💨 Abstract

An immune-boosting drug, pembrolizumab (Keytruda), extends cancer-free periods in head and neck cancer patients to an average of five years, doubling the duration compared to standard chemotherapy. The drug, used before and after surgery, reduces the risk of cancer spreading by 10%. The global trial involved 714 patients and showed significant benefits across all patients, regardless of immune marker levels.

Courtesy: www.thesun.co.uk